May 15 |
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results...
Provided Positive, Updated Data from Phase 2... |
May 09 |
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-...
30 month median overall survival (OS); median OS... |
May 09 |
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences...
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE)... |
May 07 |
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024...
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE)... |
May 03 |
PDS Biotechnology Announces Details of Virtual KOL Event...
Virtual Webinar Updated VERSATILE-002 Phase 2... |
May 02 |
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer...
Reports Inducement Grant Under Nasdaq Listing Rule... |
Apr 23 |
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial...
Company to Host Key Opinion Leader Event on May... |
Mar 27 |
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results...
Unique mechanism of action of the combination of PDS01ADC... |
Mar 20 |
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results...
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS... |
Mar 13 |
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune...
Preclinical research published inVaccines... |
Jan 22 |
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Off...
Board-certified oncologist and hematologist... |
Jan 16 |
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference...
PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS... |